Generic name: ABACAVIR SULFATE 600mg, DOLUTEGRAVIR SODIUM 50mg, LAMIVUDINE 300mg
Dosage form: tablet, film coated
Medically reviewed on November 21, 2017.
Screening for HLA-B*5701 Allele prior to Starting TRIUMEQ
Screen for the HLA‑B*5701 allele prior to initiating therapy with TRIUMEQ [see Boxed Warning, Warnings and Precautions (5.1)].
TRIUMEQ is a fixed-dose combination product containing 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine. The recommended dosage regimen of TRIUMEQ in adults and in pediatric patients weighing at least 40 kg is one tablet once daily orally with or without food.
Dosage Recommendation with Certain Concomitant Medications
The dolutegravir dose (50 mg) in TRIUMEQ is insufficient when coadministered with medications listed in Table 1 that may decrease dolutegravir concentrations; the following dolutegravir dosage regimen is recommended.
Efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampin
The recommended dolutegravir dosage regimen is 50 mg twice daily. An additional dolutegravir 50-mg tablet, separated by 12 hours from TRIUMEQ, should be taken.
Not Recommended Due to Lack of Dosage Adjustment
Because TRIUMEQ is a fixed-dose tablet and cannot be dose adjusted, TRIUMEQ is not recommended in:
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Triumeq (abacavir / dolutegravir / lamivudine)
- Triumeq Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 92 Reviews
- Drug class: antiviral combinations